{"name":"Pulmonary embolism and venous thromboembolism in COVID-19: a systematic review and meta-analysis","id":"112","link":"https://pubs.rsna.org/doi/10.1148/radiol.2020203557","dbsearches":"4","refs":"https://docs.google.com/spreadsheets/d/1KUdqYCwEAdq-FvVhcjFdmWUVhgELvDpz4u1sjbG-quw/edit#gid=0","references":[{"doi":"10.1148/radiol.2020201561","date":"1970-01-01","title":"Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels","abstract":"","id":"PMC7233397","idformat":"PMC","foundapis":"","miscinfo":"Radiological Society of North America","authors":[{"firstname":"Ian","surname":"Leonard-Lorant","email":"NULL","contributions":"1"},{"firstname":" Xavier","surname":"Delabranche","email":"NULL","contributions":"3"},{"firstname":" Xavier","surname":"Delabranche","email":"NULL","contributions":"0"},{"firstname":" François","surname":"Severac","email":"NULL","contributions":"3"},{"firstname":" François","surname":"Severac","email":"NULL","contributions":"0"},{"firstname":" Julie","surname":"Helms","email":"NULL","contributions":"0"},{"firstname":" Julie","surname":"Helms","email":"NULL","contributions":"0"},{"firstname":" Coralie","surname":"Pauzet","email":"NULL","contributions":"1"},{"firstname":" Olivier","surname":"Collange","email":"NULL","contributions":"1"},{"firstname":" Françis","surname":"Schneider","email":"NULL","contributions":"1"},{"firstname":" Aissam","surname":"Labani","email":"NULL","contributions":"2"},{"firstname":" Aissam","surname":"Labani","email":"NULL","contributions":"0"},{"firstname":" Pascal","surname":"Bilbault","email":"NULL","contributions":"1"},{"firstname":" Sébastien","surname":"Moliere","email":"NULL","contributions":"2"},{"firstname":" Sébastien","surname":"Moliere","email":"NULL","contributions":"0"},{"firstname":" Pierre","surname":"Leyendecker","email":"NULL","contributions":"1"},{"firstname":" Catherine","surname":"Roy","email":"NULL","contributions":"2"},{"firstname":" Catherine","surname":"Roy","email":"NULL","contributions":"0"},{"firstname":" Mickaël","surname":"Ohana","email":"mickael.ohana@gmail.com","contributions":"3"},{"firstname":" Mickaël","surname":"Ohana","email":"mickael.ohana@gmail.com","contributions":"0"}]},{"doi":"10.1148/radiol.2020201544","date":"1970-01-01","title":"Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography","abstract":"","id":"PMC7233384","idformat":"PMC","foundapis":"","miscinfo":"Radiological Society of North America","authors":[{"firstname":"Franck","surname":"Grillet","email":"f1grillet@chu-besancon.fr","contributions":"1"},{"firstname":" Julien","surname":"Behr","email":"NULL","contributions":"2"},{"firstname":" Julien","surname":"Behr","email":"NULL","contributions":"0"},{"firstname":" Paul","surname":"Calame","email":"NULL","contributions":"1"},{"firstname":" Sébastien","surname":"Aubry","email":"NULL","contributions":"1"},{"firstname":" Eric","surname":"Delabrousse","email":"NULL","contributions":"2"},{"firstname":" Eric","surname":"Delabrousse","email":"NULL","contributions":"0"}]},{"doi":"10.1007/s00330-020-06977-5","date":"2020-05-20","title":"Acute pulmonary embolism in non-hospitalized COVID-19 patients referred to CTPA by emergency department","abstract":"Objectives\nid='Par1'>To evaluate the prevalence of acute pulmonary embolism (APE) in non-hospitalized COVID-19 patients referred to CT pulmonary angiography (CTPA) by the emergency department.\n\n\nMethods\nid='Par2'>From March 14 to April 6, 2020, 72 non-hospitalized patients referred by the emergency department to CTPA for COVID-19 pneumonia were retrospectively identified.\n\n Relevant clinical and laboratory data and CT scan findings were collected for each patient.\n\n CTPA scans were reviewed by two radiologists to determinate the presence or absence of APE.\n\n Clinical classification, lung involvement of COVID-19 pneumonia, and CT total severity score were compared between APE group and non-APE group.\n\n\nResults\nid='Par3'>APE was identified in 13 (18%) CTPA scans.\n\n The mean age and D-dimer of patients from the APE group were higher in comparison with those from the non-APE group (74.4 vs.\n\n 59.6 years, p?=?0.008, and 7.29 vs.\n\n 3.29 ?g/ml, p?=?0.011).\n\n There was no significant difference between APE and non-APE groups concerning clinical type, COVID-19 pneumonia lung lesions (ground-glass opacity: 85% vs.\n\n 97%; consolidation: 69% vs.\n\n 68%; crazy paving: 38% vs.\n\n 37%; linear reticulation: 69% vs.\n\n 78%), CT severity score (6.3 vs.\n\n 7.1, p?=?0.365), quality of CTPA (1.8 vs.\n\n 2.0, p?=?0.518), and pleural effusion (38% vs.\n\n 19%, p?=?0.146).\n\n\nConclusions\nid='Par4'>Non-hospitalized patients with COVID-19 pneumonia referred to CT scan by the emergency departments are at risk of APE.\n\n The presence of APE was not limited to severe or critical clinical type of COVID-19 pneumonia.\n\n\nKey Points\nid='Par5'>\n• Acute pulmonary embolism was found in 18% of non-hospitalized COVID-19 patients referred by the emergency department to CTPA.\n\n Two (15%) patients had main, four (30%) lobar, and seven (55%) segmental acute pulmonary embolism.\n\n\n\n","id":"PMC7280685","idformat":"PMC","foundapis":"","miscinfo":"Springer Berlin Heidelberg","authors":[{"firstname":"Alban","surname":"Gervaise","email":"alban.gervaise@hotmail.fr","contributions":"1"},{"firstname":" Caroline","surname":"Bouzad","email":"NULL","contributions":"2"},{"firstname":" Caroline","surname":"Bouzad","email":"NULL","contributions":"0"},{"firstname":" Evelyne","surname":"Peroux","email":"NULL","contributions":"1"},{"firstname":" Carole","surname":"Helissey","email":"NULL","contributions":"1"}]},{"doi":"10.1182/blood.2020006520","date":"2020-05-24","title":"COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection","abstract":"Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels.\n Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited.\n This multicenter retrospective study describes the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation.\n Coagulation and inflammatory parameters were compared between patients with and without coagulation-associated complications.\n Multivariable logistic models examined the utility of these markers in predicting coagulation-associated complications, critical illness, and death.\n The radiographically confirmed VTE rate was 4.8% (95% confidence interval [CI], 2.9-7.3), and the overall thrombotic complication rate was 9.5% (95% CI, 6.8-12.8).\n The overall and major bleeding rates were 4.8% (95% CI, 2.9-7.3) and 2.3% (95% CI, 1.0-4.2), respectively.\n In the critically ill, radiographically confirmed VTE and major bleeding rates were 7.6% (95% CI, 3.9-13.3) and 5.6% (95% CI, 2.4-10.7), respectively.\n Elevated D-dimer at initial presentation was predictive of coagulation-associated complications during hospitalization (D-dimer &gt;2500 ng/mL, adjusted odds ratio [OR] for thrombosis, 6.79 [95% CI, 2.39-19.30]; adjusted OR for bleeding, 3.56 [95% CI, 1.01-12.66]), critical illness, and death.\n Additional markers at initial presentation predictive of thrombosis during hospitalization included platelet count &gt;450 × 109/L (adjusted OR, 3.56 [95% CI, 1.27-9.97]), C-reactive protein (CRP) &gt;100 mg/L (adjusted OR, 2.71 [95% CI, 1.26-5.86]), and erythrocyte sedimentation rate (ESR) &gt;40 mm/h (adjusted OR, 2.64 [95% CI, 1.07-6.51]).\n ESR, CRP, fibrinogen, ferritin, and procalcitonin were higher in patients with thrombotic complications than in those without.\n DIC, clinically relevant thrombocytopenia, and reduced fibrinogen were rare and were associated with significant bleeding manifestations.\n Given the observed bleeding rates, randomized trials are needed to determine any potential benefit of intensified anticoagulant prophylaxis in COVID-19 patients.\n","id":"PMC7378457","idformat":"PMC","foundapis":"","miscinfo":"American Society of Hematology","authors":[{"firstname":"Hanny","surname":"Al-Samkari","email":"NULL","contributions":"1"},{"firstname":" Rebecca S.","surname":"Karp Leaf","email":"NULL","contributions":"1"},{"firstname":" Walter H.","surname":"Dzik","email":"NULL","contributions":"1"},{"firstname":" Jonathan C.T.","surname":"Carlson","email":"NULL","contributions":"1"},{"firstname":" Annemarie E.","surname":"Fogerty","email":"NULL","contributions":"1"},{"firstname":" Anem","surname":"Waheed","email":"NULL","contributions":"1"},{"firstname":" Katayoon","surname":"Goodarzi","email":"NULL","contributions":"1"},{"firstname":" Pavan K.","surname":"Bendapudi","email":"NULL","contributions":"1"},{"firstname":" Larissa","surname":"Bornikova","email":"NULL","contributions":"1"},{"firstname":" Shruti","surname":"Gupta","email":"NULL","contributions":"1"},{"firstname":" David E.","surname":"Leaf","email":"NULL","contributions":"1"},{"firstname":" David J.","surname":"Kuter","email":"NULL","contributions":"1"},{"firstname":" Rachel P.","surname":"Rosovsky","email":"NULL","contributions":"1"}]},{"doi":"10.1161/CIRCULATIONAHA.120.047407","date":"1970-01-01","title":"Unknown Title","abstract":"Unknown Abstract","id":"not found","idformat":"N/A","foundapis":"","miscinfo":"","authors":[]},{"doi":"10.1161/CIRCULATIONAHA.120.046702","date":"1970-01-01","title":"Unknown Title","abstract":"Unknown Abstract","id":"not found","idformat":"N/A","foundapis":"","miscinfo":"","authors":[]},{"doi":"10.1111/jth.14869","date":"2020-04-20","title":"High incidence of venous thromboembolic events in anticoagulated severe COVID?19 patients","abstract":"Background\nCoagulopathy is a common abnormality in patients with COVID?19. However, the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe COVID?19 patients.\n\n\nObjectives\nSystematic assessment of venous thromboembolism (VTE) using complete duplex ultrasound (CDU) in anticoagulated COVID?19 patients.\n\n\nPatients and methods\nWe performed a retrospective study in 2 French intensive care units (ICU) where CDU is performed as a standard of care.\n\n A CDU from thigh to ankle at selected sites with Doppler waveforms and images was performed early during ICU stay in patients admitted with COVID?19. Anticoagulation dose was left to the discretion of the treating physician based on the individual risk of thrombosis.\n\n Patients were classified as treated with prophylactic anticoagulation or therapeutic anticoagulation.\n\n Pulmonary embolism was systematically searched in patients with persistent hypoxemia or secondary deterioration.\n\n\nResults\nFrom March 19 to April 11, 2020, 26 consecutive patients with severe COVID?19 were screened for VTE.\n\n Eight patients (31%) were treated with prophylactic anticoagulation, whereas 18 patients (69%) were treated with therapeutic anticoagulation.\n\n The overall rate of VTE in patients was 69%.\n\n The proportion of VTE was significantly higher in patients treated with prophylactic anticoagulation when compared with the other group (100% vs 56%, respectively, P = .\n\n03).\n\n Surprisingly, we found a high rate of thromboembolic events in COVID?19 patients treated with therapeutic anticoagulation, with 56% of VTE and 6 pulmonary embolisms.\n\n\nConclusion\nOur results suggest considering both systematic screening of VTE and early therapeutic anticoagulation in severe ICU COVID?19 patients.\n\n\n","id":"PMC7264774","idformat":"PMC","foundapis":"","miscinfo":"International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","authors":[{"firstname":"Jean?François","surname":"Llitjos","email":"NULL","contributions":"1"},{"firstname":" Maxime","surname":"Leclerc","email":"NULL","contributions":"0"},{"firstname":" Camille","surname":"Chochois","email":"NULL","contributions":"1"},{"firstname":" Jean?Michel","surname":"Monsallier","email":"NULL","contributions":"1"},{"firstname":" Michel","surname":"Ramakers","email":"NULL","contributions":"0"},{"firstname":" Malika","surname":"Auvray","email":"NULL","contributions":"1"},{"firstname":" Karim","surname":"Merouani","email":"NULL","contributions":"1"}]},{"doi":"10.1007/s00134-020-06062-x","date":"2020-04-17","title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","abstract":"Purpose\nid='Par1'>Little evidence of increased thrombotic risk is available in COVID-19 patients.\n\n Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection.\n\n\nMethods\nid='Par2'>All patients referred to 4 intensive care units (ICUs) from two centers of a French tertiary hospital for acute respiratory distress syndrome (ARDS) due to COVID-19 between March 3rd and 31st 2020 were included.\n\n Medical history, symptoms, biological data and imaging were prospectively collected.\n\n Propensity score matching was performed to analyze the occurrence of thromboembolic events between non-COVID-19 ARDS and COVID-19 ARDS patients.\n\n\nResults\nid='Par3'>150 COVID-19 patients were included (122 men, median age 63 [53; 71] years, SAPSII 49 [37; 64] points).\n\n Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%).\n\n 28/29 patients (96.6%) receiving continuous renal replacement therapy experienced circuit clotting.\n\n Three thrombotic occlusions (in 2 patients) of centrifugal pump occurred in 12 patients (8%) supported by ECMO.\n\n Most patients (&gt;?95%) had elevated D-dimer and fibrinogen.\n\n No patient developed disseminated intravascular coagulation.\n\n Von Willebrand (vWF) activity, vWF antigen and FVIII were considerably increased, and 50/57 tested patients (87.7%) had positive lupus anticoagulant.\n\n Comparison with non-COVID-19 ARDS patients (n?=?145) confirmed that COVID-19 ARDS patients (n?=?77) developed significantly more thrombotic complications, mainly pulmonary embolisms (11.7 vs.\n\n 2.1%, p?&lt;?0.008).\n\n Coagulation parameters significantly differed between the two groups.\n\n\nConclusion\nid='Par4'>Despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications.\n\n Higher anticoagulation targets than in usual critically ill patients should therefore probably be suggested.\n\n\nElectronic supplementary material\nThe online version of this article (10.1007/s00134-020-06062-x) contains supplementary material, which is available to authorized users.\n\n\n","id":"PMC7197634","idformat":"PMC","foundapis":"","miscinfo":"Springer Berlin Heidelberg","authors":[{"firstname":"Julie","surname":"Helms","email":"NULL","contributions":"1"},{"firstname":" Charles","surname":"Tacquard","email":"NULL","contributions":"1"},{"firstname":" François","surname":"Severac","email":"NULL","contributions":"0"},{"firstname":" Ian","surname":"Leonard-Lorant","email":"NULL","contributions":"1"},{"firstname":" Mickaël","surname":"Ohana","email":"NULL","contributions":"0"},{"firstname":" Xavier","surname":"Delabranche","email":"NULL","contributions":"0"},{"firstname":" Hamid","surname":"Merdji","email":"NULL","contributions":"1"},{"firstname":" Raphaël","surname":"Clere-Jehl","email":"NULL","contributions":"1"},{"firstname":" Malika","surname":"Schenck","email":"NULL","contributions":"1"},{"firstname":" Florence","surname":"Fagot Gandet","email":"NULL","contributions":"1"},{"firstname":" Samira","surname":"Fafi-Kremer","email":"NULL","contributions":"0"},{"firstname":" Vincent","surname":"Castelain","email":"NULL","contributions":"0"},{"firstname":" Francis","surname":"Schneider","email":"NULL","contributions":"0"},{"firstname":" Lélia","surname":"Grunebaum","email":"NULL","contributions":"1"},{"firstname":" Eduardo","surname":"Anglés-Cano","email":"NULL","contributions":"1"},{"firstname":" Laurent","surname":"Sattler","email":"NULL","contributions":"1"},{"firstname":" Paul-Michel","surname":"Mertes","email":"NULL","contributions":"0"},{"firstname":" Ferhat","surname":"Meziani","email":"Ferhat.Meziani@chru-strasbourg.fr","contributions":"1"},{"firstname":" NULL","surname":"NULL","email":"NULL","contributions":"0"}]},{"doi":"10.1016/j.thromres.2020.05.018","date":"2020-05-12","title":"Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels<","abstract":"Aim\nAn increased risk of venous thromboembolism (VTE) in patients with COVID-19 pneumonia admitted to intensive care unit (ICU) has been reported.\n\n Whether COVID-19 increases the risk of VTE in non-ICU wards remains unknown.\n\n We aimed to evaluate the burden of asymptomatic deep vein thrombosis (DVT) in COVID-19 patients with elevated D-dimer levels.\n\n\nMethod\nIn this prospective study consecutive patients hospitalized in non-intensive care units with diagnosis of COVID-19 pneumonia and D-dimer?&gt;?1000?ng/ml were screened for asymptomatic DVT with complete compression doppler ultrasound (CCUS).\n\n The study was approved by the Institutional Ethics Committee.\n\n\nResults\nThe study comprised 156 patients (65.4% male).\n\n All but three patients received standard doses of thromboprophylaxis.\n\n Median days of hospitalization until CCUS was 9 (IQR 5–17).\n\n CCUS was positive for DVT in 23 patients (14.7%), of whom only one was proximal DVT.\n\n Seven patients (4.5%) had bilateral distal DVT.\n\n Patients with DVT had higher median D-dimer levels: 4527 (IQR 1925-9144) ng/ml vs 2050 (IQR 1428-3235) ng/ml; p?&lt;?0.001. D-dimer levels?&gt;?1570?ng/ml were associated with asymptomatic DVT (OR 9.1; CI 95% 1.1–70.1).\n\n D-dimer showed an acceptable discriminative capacity (area under the ROC curve 0.72, 95% CI 0.61–0.84).\n\n\nConclusion\nIn patients admitted with COVID-19 pneumonia and elevated D-dimer levels, the incidence of asymptomatic DVT is similar to that described in other series.\n\n Higher cut-off levels for D-dimer might be necessary for the diagnosis of DVT in COVID-19 patients.\n\n\n","id":"PMC7219400","idformat":"PMC","foundapis":"","miscinfo":"Elsevier Ltd.","authors":[{"firstname":"P.","surname":"Demelo-Rodríguez","email":"NULL","contributions":"1"},{"firstname":" E.","surname":"Cervilla-Muñoz","email":"NULL","contributions":"1"},{"firstname":" L.","surname":"Ordieres-Ortega","email":"NULL","contributions":"1"},{"firstname":" A.","surname":"Parra-Virto","email":"NULL","contributions":"1"},{"firstname":" M.","surname":"Toledano-Macías","email":"NULL","contributions":"1"},{"firstname":" N.","surname":"Toledo-Samaniego","email":"NULL","contributions":"1"},{"firstname":" A.","surname":"García-García","email":"NULL","contributions":"1"},{"firstname":" I.","surname":"García-Fernández-Bravo","email":"NULL","contributions":"1"},{"firstname":" Z.","surname":"Ji","email":"NULL","contributions":"1"},{"firstname":" J.","surname":"de-Miguel-Diez","email":"NULL","contributions":"1"},{"firstname":" L.A.","surname":"Álvarez-Sala-Walther","email":"NULL","contributions":"1"},{"firstname":" J.","surname":"del-Toro-Cervera","email":"NULL","contributions":"1"},{"firstname":" F.","surname":"Galeano-Valle","email":"paco.galeano.valle@gmail.com","contributions":"1"}]},{"doi":"10.1111/jth.14830","date":"2020-04-04","title":"Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia","abstract":"Background\nThree months ago, severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2) broke out in Wuhan, China, and spread rapidly around the world.\n\n Severe novel coronavirus pneumonia (NCP) patients have abnormal blood coagulation function, but their venous thromboembolism (VTE) prevalence is still rarely mentioned.\n\n\nObjectives\nTo determine the incidence of VTE in patients with severe NCP.\n\n\nMethods\nIn this study, 81 severe NCP patients in the intensive care unit (ICU) of Union Hospital (Wuhan, China) were enrolled.\n\n The results of conventional coagulation parameters and lower limb vein ultrasonography of these patients were retrospectively collected and analyzed.\n\n\nResults\nThe incidence of VTE in these patients was 25% (20/81), of which 8 patients with VTE events died.\n\n The VTE group was different from the non?VTE group in age, lymphocyte counts, activated partial thromboplastin time (APTT), D?dimer, etc.\n\n If 1.5 µg/mL was used as the D?dimer cut?off value to predicting VTE, the sensitivity was 85.0%, the specificity was 88.5%, and the negative predictive value (NPV) was 94.7%.\n\n\nConclusions\nThe incidence of VTE in patients with severe NCP is 25% (20/81), which may be related to poor prognosis.\n\n The significant increase of D?dimer in severe NCP patients is a good index for identifying high?risk groups of VTE.\n\n\n","id":"PMC7262324","idformat":"PMC","foundapis":"","miscinfo":"International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","authors":[{"firstname":"Songping","surname":"Cui","email":"NULL","contributions":"1"},{"firstname":" Shuo","surname":"Chen","email":"NULL","contributions":"1"},{"firstname":" Xiunan","surname":"Li","email":"NULL","contributions":"1"},{"firstname":" Shi","surname":"Liu","email":"NULL","contributions":"1"},{"firstname":" Feng","surname":"Wang","email":"NULL","contributions":"0"}]},{"doi":"10.1111/jth.14888","date":"2020-05-01","title":"Incidence of venous thromboembolism in hospitalized patients with COVID?19","abstract":"Background\nCoronavirus disease 2019 (COVID?19) can lead to systemic coagulation activation and thrombotic complications.\n\n\nObjectives\nTo investigate the incidence of objectively confirmed venous thromboembolism (VTE) in hospitalized patients with COVID?19.\nMethods\nSingle?center cohort study of 198 hospitalized patients with COVID?19.\nResults\nSeventy?five patients (38%) were admitted to the intensive care unit (ICU).\n\n At time of data collection, 16 (8%) were still hospitalized and 19% had died.\n\n During a median follow?up of 7 days (IQR, 3?13), 39 patients (20%) were diagnosed with VTE of whom 25 (13%) had symptomatic VTE, despite routine thrombosis prophylaxis.\n\n The cumulative incidences of VTE at 7, 14 and 21 days were 16% (95% CI, 10?22), 33% (95% CI, 23?43) and 42% (95% CI 30?54) respectively.\n\n For symptomatic VTE, these were 10% (95% CI, 5.8?16), 21% (95% CI, 14?30) and 25% (95% CI 16?36).\n\n VTE appeared to be associated with death (adjusted HR, 2.4; 95% CI, 1.02?5.5).\n\n The cumulative incidence of VTE was higher in the ICU (26% (95% CI, 17?37), 47% (95% CI, 34?58), and 59% (95% CI, 42?72) at 7, 14 and 21 days) than on the wards (any VTE and symptomatic VTE 5.8% (95% CI, 1.4?15), 9.2% (95% CI, 2.6?21), and 9.2% (2.6?21) at 7, 14, and 21 days).\n\n\nConclusions\nThe observed risk for VTE in COVID?19 is high, particularly in ICU patients, which should lead to a high level of clinical suspicion and low threshold for diagnostic imaging for DVT or PE.\n\n Future research should focus on optimal diagnostic and prophylactic strategies to prevent VTE and potentially improve survival.\n\n\n","id":"PMC7497052","idformat":"PMC","foundapis":"","miscinfo":"The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","authors":[{"firstname":"Saskia","surname":"Middeldorp","email":"NULL","contributions":"1"},{"firstname":" Michiel","surname":"Coppens","email":"NULL","contributions":"1"},{"firstname":" Thijs F.","surname":"van Haaps","email":"NULL","contributions":"1"},{"firstname":" Merijn","surname":"Foppen","email":"NULL","contributions":"1"},{"firstname":" Alexander P.","surname":"Vlaar","email":"NULL","contributions":"1"},{"firstname":" Marcella C.A.","surname":"Müller","email":"NULL","contributions":"1"},{"firstname":" Catherine C.S.","surname":"Bouman","email":"NULL","contributions":"1"},{"firstname":" Ludo F.M.","surname":"Beenen","email":"NULL","contributions":"1"},{"firstname":" Ruud S.","surname":"Kootte","email":"NULL","contributions":"1"},{"firstname":" Jarom","surname":"Heijmans","email":"NULL","contributions":"1"},{"firstname":" Loek P.","surname":"Smits","email":"NULL","contributions":"1"},{"firstname":" Peter I.","surname":"Bonta","email":"NULL","contributions":"1"},{"firstname":" Nick","surname":"van Es","email":"NULL","contributions":"1"}]},{"doi":"10.1161/CIRCULATIONAHA.120.047430","date":"1970-01-01","title":"Unknown Title","abstract":"Unknown Abstract","id":"not found","idformat":"N/A","foundapis":"","miscinfo":"","authors":[]},{"doi":"10.1183/13993003.01365-2020","date":"2020-04-29","title":"Pulmonary embolism in patients with COVID-19 pneumonia","abstract":"Acute respiratory distress syndrome development in patients with coronavirus disease 2019 (COVID-19) pneumonia is associated with a high mortality rate and is the main cause of death in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1].\n Myocardial injury has also been reported to be significantly associated with fatal outcome, with a 37% mortality rate in patients without prior cardiovascular disease but elevated troponin levels [2].\n A D-dimer level of &gt;1??g·mL?1 has been clearly identified as a risk factor for poor outcome in SARS-Cov-2 infection [3], with recent reports highlighting a high incidence of thrombotic events in intensive care unit (ICU) patients [4].\n A normal D-dimer level allows the safe exclusion of pulmonary embolism (PE) in outpatients with a low or intermediate clinical probability of PE, but there is no recommendation to use D-dimer as a positive marker of thrombosis because of lack of specificity.\n","id":"PMC7236820","idformat":"PMC","foundapis":"","miscinfo":"European Respiratory Society","authors":[{"firstname":"Florian","surname":"Bompard","email":"NULL","contributions":"1"},{"firstname":" Hippolyte","surname":"Monnier","email":"NULL","contributions":"1"},{"firstname":" Ines","surname":"Saab","email":"NULL","contributions":"1"},{"firstname":" Mickael","surname":"Tordjman","email":"NULL","contributions":"1"},{"firstname":" Hendy","surname":"Abdoul","email":"NULL","contributions":"1"},{"firstname":" Laure","surname":"Fournier","email":"NULL","contributions":"1"},{"firstname":" Olivier","surname":"Sanchez","email":"NULL","contributions":"1"},{"firstname":" Christine","surname":"Lorut","email":"NULL","contributions":"1"},{"firstname":" Guillaume","surname":"Chassagnon","email":"NULL","contributions":"1"},{"firstname":" Marie-Pierre","surname":"Revel","email":"NULL","contributions":"1"}]},{"doi":"10.1055/s-0040-1712097","date":"2020-04-23","title":"Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?","abstract":"","id":"PMC7516356","idformat":"PMC","foundapis":"","miscinfo":"Georg Thieme Verlag KG","authors":[{"firstname":"Marco","surname":"Cattaneo","email":"NULL","contributions":"1"},{"firstname":" Elena M.","surname":"Bertinato","email":"NULL","contributions":"1"},{"firstname":" Simone","surname":"Birocchi","email":"NULL","contributions":"1"},{"firstname":" Carolina","surname":"Brizio","email":"NULL","contributions":"1"},{"firstname":" Daniele","surname":"Malavolta","email":"NULL","contributions":"1"},{"firstname":" Marco","surname":"Manzoni","email":"NULL","contributions":"1"},{"firstname":" Gesualdo","surname":"Muscarella","email":"NULL","contributions":"1"},{"firstname":" Michela","surname":"Orlandi","email":"NULL","contributions":"1"}]}]}